United Therapeutics Corporation logo

Senior/Advanced Lung Disease Sales Specialist (Houston, TX) *Rare Disease Opportunity*

United Therapeutics Corporation
July 01, 2026
Remote friendly (Houston, TX)
United States
Sales
Advanced Lung Disease (ALD) Specialist β€” Houston, TX area (remote); 75–80% travel.

Responsibilities:
- Promote Tyvaso and other UT products per corporate guidance within assigned territory/accounts.
- Build and maintain relationships with HCPs and specialty distributor staff; provide product messaging and education for PH-ILD and/or IPF.
- Analyze sales reports and develop business plans to achieve/exceed sales targets in key accounts.
- Coordinate with field-based teams (e.g., RBD) to optimize selling and support efforts.
- Maintain expert knowledge of disease state, products, and competitive landscape.
- Use sales force automation for territory effectiveness and record-keeping.
- Complete administrative requirements (e.g., expense and call reporting) and adhere to corporate/external regulatory/UT promotion guidelines.
- Attend relevant symposia/conferences and patient support group meetings; participate in sales/marketing project teams as directed.

Minimum Requirements (ALD Specialist):
- Bachelor’s degree (nursing/life science preferred) or equivalent experience.
- 6+ years specialty pharmaceutical sales (or 6+ years advanced lung disease healthcare/nursing experience).
- 2+ years Cardiovascular and/or Pulmonary therapeutics area expertise.
- Strong leader; proven selling and communication skills; decision-making/planning/interpersonal skills.
- Knowledge of UT products/services; valid driver’s license.

Preferred (ALD Specialist): 2+ years specialty biotech sales; 2+ years PH-ILD and/or IPF sales; 2+ years institutional/major teaching centers.

Salary & Benefits (per posting): Base salary $130,000–$160,000 (ALD) or $155,000–$180,000 (Sr. ALD); comprehensive benefits including medical/dental/vision/prescription, wellness, 401(k)/ESPP, paid time off/paid parental leave, disability, and more.